ライフサイエンスコーパス: renal

1 eline tumor samples from the phase 3 JAVELIN Renal 101 trial (n = 886; NCT02684006 ), which demonstra

2 Renal (39.8%), gastrointestinal (24.1%), bone (22.9%), a

3 We propose that renal accumulation of pro-oxidant elements such as arsen

4 ablation of renal nerves results in reduced renal afferent and efferent sympathetic nerve activity i

5 n as well as isolated Klippel-Feil syndrome, renal agenesis or esophageal atresia.

6 ory B cell-derived HLA antibodies (DSA-M) in renal allograft recipients with pretransplant donor-spec

7 cular profiling in the setting of diagnosing renal allograft rejection and how this will improve tran

8 Renal allograft rejection is more frequent under belatac

9 body (DSA) has been associated with improved renal allograft survival after antibody-mediated rejecti

10 Renal and cardiac responses occurred in 8 and 7 patients

11 e 2 diabetes, DKD is associated with reduced renal and cardiac superoxide levels and that MTP-131 pro

12 avorable clinical condition that accelerates renal and cardiovascular disease.

13 livered using clinical catheters to embolize renal and iliac arteries, and it can achieve rapid hemos

14 ding cardiac, vertebral, tracheo-esophageal, renal and limb defects.

15 other severe damage such as cardiovascular, renal and liver injury or/and multiple organ failure, su

16 In renal and lung cancer patients, the presence of the ente

17 investigate relationships between sTNFR1 and renal and mortality endpoints by multivariable linear mi

18 ng clinical trials with promising results in renal and other cancers where HIF-2 is considered to be

19 add to the clinical assessment in predicting renal and patient outcomes in LCCN is uncertain.

20 d the attention toward the gastrointestinal, renal, and cardiovascular toxicity.

21 oups (cardiovascular, hematology, pulmonary, renal, and endocrine).

22 any diseases besides cancer, including lung, renal, and neurodevelopmental disorders.

23 l therapy (MT) and percutaneous transluminal renal angioplasty (MT + PTRA) (n = 11, 3 bilaterally, n

24 phatase, creatinine, and improved liver, and renal antioxidative status.

25 Multiple renal arteries were present in 24.1%.

26 warm in situ ischemia by cross-clamping the renal arteries.

27 Whereas direct delivery, such as renal artery injection requires surgical procedures.

28 ld standard in the diagnostics of transplant renal artery stenosis (TRAS).

29 th gold nanorods (GNR) and injected into the renal artery using ultrasound guidance.

30 ,630 hospitalized patients undergoing native renal biopsy between January 1, 2009 and December 31, 20

31 Whether renal biopsy findings add to the clinical assessment in

32 ., chicken thigh muscle with skin and murine renal biopsy including medulla (M) and cortex (C)) showe

33 sembly and increases migratory propensity in renal cancer cells.

34 ase (FH) associates with a malignant form of renal cancer characterized by fumarate accumulation and

35 encing of the transcription factor PRDM16 in renal cancer.

36 tients with stage IV lung carcinomas (n=24), renal carcinomas (n=11), or melanoma (n=44) treated with

37 GFR), end-stage renal disease, or death from renal causes), the individual components of this composi

38 nts with a prior diagnosis of breast cancer, renal cell cancer, or leukemia underwent whole-body PET/

39 umab + axitinib versus sunitinib in advanced renal cell carcinoma (aRCC).

40 in mouse models of CAIX-positive clear cell renal cell carcinoma (ccRCC) and colorectal cancer.

41 The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by geneti

42 been termed a tumor-suppressor in clear cell renal cell carcinoma (ccRCC), primarily based on functio

43 ressor and is highly expressed in clear cell renal cell carcinoma (ccRCC), where SLC2A3 expression is

44 during tumour initiation and progression in renal cell carcinoma (RCC) and three oncometabolites - f

45 Renal cell carcinoma (RCC) incidence is increasing world

46 Human renal cell carcinoma (RCC) tumors were stained for the N

47 Eligible patients had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous

48 rs (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC).

49 Pre-treatment determination of renal cell carcinoma aggressiveness may help guide clini

50 neous CT- and MRI-guided cryoablation of cT1 renal cell carcinoma had similar excellent intermediate-

51 dominant ganglioside isolated from malignant renal cell carcinoma tissues, is reported.

52 nign skin tumours, lung and kidney cysts and renal cell carcinoma(6,7).

53 is associated with other malignancies (e.g. renal cell carcinoma), little is known about the role of

54 olizumab in patients with mUC and metastatic renal cell carcinoma, even in tumors that were classical

55 ic target for the treatment of VHL-deficient renal cell carcinoma.

56 cluding normal kidney, renal oncocytoma, and renal cell carcinomas (RCC).

57 t can occur in most histological subtypes of renal cell carcinomas (RCCs) and carries a decidedly poo

58 For instance, ALK-rearranged renal cell carcinomas have shown responses to alectinib

59 t to all targeted agents used to treat other renal cell carcinomas.

60 tity cells" (expressing markers of different renal cell types) that are normally seen only during ear

61 This review will focus on the role of S1P in renal cells and how aberrant extracellular and intracell

62 he intracellular sphingolipid composition of renal cells is an important determinant of renal functio

63 By virtue of their ideal renal clearance efficiency (60% injected doses at 24 h p

64 rasmall size of Cu(5.4)O USNPs enables rapid renal clearance of the nanomaterial, guaranteeing the bi

65 Early identification of augmented renal clearance remains challenging for the ICU physicia

66 Biodistribution showed fast renal clearance.

67 th that of two existing models for augmented renal clearance.

68 ) progression, implicating mechanisms beyond renal clearance.

69 29-2.737; p = 0.864; overall p = 0.017), and renal complications on extracorporeal membrane oxygenati

70 , we present the results of the prespecified renal composite outcome (time to first occurrence of eit

71 ibition in treating pathological cardiac and renal conditions, mechanistic understanding of TRPC6 fun

72 H(2) O(2) production was reduced in both the renal cortex and medulla in SS(Nox4-/-) rats fed an HS d

73 0.5 +/- 3% of the introduced capsules in the renal cortex glomeruli.

74 (tubulo-interstitial) renal lesions in total renal cortex.

75 Patients in ARISTOTLE without severe renal (creatine clearance <=30 mL/min) or liver disease

76 Administration of SCFAs reduced renal crystals.

77 on County Health Rankings, the United States Renal Data System, and the Scientific Registry of Transp

78 In a case-control study nested within the US Renal Data System, we identified all hip fracture events

79 005 and 2014, according to the United States Renal Data System.

80 group and from 150 mm Hg to 135 mm Hg in the renal denervation group (between-group difference, -13 m

81 IGN, SETTING, AND PARTICIPANTS: The Evaluate Renal Denervation in Addition to Catheter Ablation to El

82 Renal denervation is an endovascular procedure, whereby

83 Despite the crucial role of Pax2 in renal development, functions for Pax2 or Pax8 in adult r

84 gnosis compared with other cardiovascular or renal diagnoses in patients with T2D.

85 ared with 1.5%; p = 0.0041), and preexisting renal disease (9.1% compared with 3.0%; p < 0.0001) had

86 endent predictor of posttransplant end-stage renal disease (ESRD) and mortality.

87 s for severe infection included pre-existing renal disease (odds ratio [OR], 7.4; 95% CI, 2.5-22.0),

88 Both modification of diet in renal disease and Cockcroft-Gault equations displayed th

89 ogic assays characterize the presentation of renal disease and enable useful pharmacologic interventi

90 arch, therapeutic options to halt or reverse renal disease are rather limited.

91 Nine patients (42%) had end stage renal disease at a mean age of 10.6 years (6.5-17 years)

92 undergoing peritoneal dialysis for end-stage renal disease but without cirrhosis were included as con

93 ubsequent fatal and non-fatal cardiovascular/renal disease events in AA subjects.

94 e subsequent incidence of cardiovascular and renal disease events, follow-up information was obtained

95 he GRS performed better in the prediction of renal disease in the 'later onset' compared with the 'ea

96 Patient survival with end-stage renal disease is longer after kidney transplantation (KT

97 etes and to assess if the presence of cardio-renal disease modifies these relationships.

98 l antibody tesidolumab (LFG316) in end-stage renal disease patients awaiting kidney transplant.

99 ted research has been conducted on end-stage renal disease patients.

100 In up to 15 years, follow-up end-stage renal disease was observed in 1 LD versus 7 THIN (P = 0.

101 People with T2D without cardio-renal disease would be predicted to benefit greatly from

102 ipoprotein cholesterol levels, hypertension, renal disease, age, and sex.

103 cardiovascular disease, end-stage liver and renal disease, death) was compared between regimens usin

104 pairment and Imaging Correlates in End Stage Renal Disease, NCT01883349.

105 glomerular filtration rate (eGFR), end-stage renal disease, or death from renal causes), the individu

106 erpretation of urine protein measurements in renal disease.

107 receptors in causing pain during diabetes or renal disease.

108 heart failure hospitalization and end-stage renal disease.

109 tions, and tissue repair and regeneration in renal diseases.

110 ecules was shown to be promising in treating renal diseases.

111 high blood levels in patients with advanced renal diseases.

112 D-Dimer cutoff levels adjusted for renal dysfunction appear feasible and safe assessing thr

113 long-term benefit over SAR in patients with renal dysfunction who require CABG.

114 topenia, anasarca, fever, reticulin fibrosis/renal dysfunction, and organomegaly.

115 rrest, pulmonary edema on chest x-ray, acute renal dysfunction, bleeding requiring transfusion or int

116 t in those without TG despite other forms of renal dysfunction.

117 2) scores 4 to 6, and patients with moderate renal dysfunction.

118 h acute kidney injury and "acute on chronic" renal dysfunction.

119 lopment, functions for Pax2 or Pax8 in adult renal epithelia have not been established.

120 Ectopic expression of Akap12 in renal epithelia results in abnormally long primary cilia

121 al novel functions for Pax proteins in adult renal epithelia that are essential for retaining water a

122 we show that ablation of HNF-1beta in mIMCD3 renal epithelial cells results in activation of beta-cat

123 a mechanism by which GRK4, via regulation of renal ETBR function, participates in the pathogenesis of

124 over clinic BP in predicting cardiovascular/renal events, which was limited to making a difference o

125 ively, at 1 h after injection), indicating a renal excretion pathway.

126 eted treatment available and, in some cases, renal failure is unavoidable.

127 cardiac arrest (10%), sepsis (7%), and acute renal failure requiring dialysis (3%).

128 The general assessment revealed a renal failure symptomatic of a nephrotic syndrome, assoc

129 rparathyroidism, multiglandular disease, and renal failure were excluded.

130 EC) infection causes severe bloody diarrhea, renal failure, and hemolytic uremic syndrome.

131 itus, osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular diseas

132 ive GN and 15,614 individuals with nonimmune renal failure.

133 by hypoxic respiratory failure and oliguric renal failure.

134 age, 34.1% on anticoagulants, and 14.7% with renal failure.

135 crescentic glomerulonephritis, and end-stage renal failure.

136 ditary disorder characterized by progressive renal failure.

137 diabetes and the leading cause of end-stage renal failure.

138 rovide important insights into understanding renal fibrosis and antifibrotic strategies.

139 ion of HE4 overexpression in hypoxia-induced renal fibrosis will provide important insights into unde

140 and mechanisms of HE4 in the pathogenesis of renal fibrosis.

141 novel therapeutic approach for treatment of renal fibrosis.

142 r primary nonfunction (PNF; n = 37) and poor renal function (estimated glomerular filtration rate < 3

143 Less than 50% of patients with normal renal function achieve this exposure, and it is associat

144 ex (aircraft, road traffic Lden, and PM2.5), renal function and "allostatic load" (all exposures).

145 Renal function and donor-specific HLA-antibodies remaine

146 t graft loss in patients who showed a stable renal function at the day of biopsy.

147 A prospective study of renal function before and after aortic stent-graft treat

148 Proteinuria is associated with renal function decline and cardiovascular mortality.

149 Hypertension often occurs before renal function deteriorates in autosomal dominant polycy

150 (CSC, n=446): patients developing new-onset renal function deterioration 7.7 +/- 5.6 years posttrans

151 Patients with ALD and impaired renal function have a higher risk of graft loss and deat

152 tissue damage at systemic level and improved renal function in conditioned groups compared to control

153 Pool walking may improve renal function in pregnant women partly through the supp

154 same hospitalisation) significantly worsened renal function in the late follow-up and should be avoid

155 Clinical renal function measures included estimated glomerular fi

156 However, the markers of renal function of the Ep group were detected slightly im

157 by SIR-based early CNI minimization protects renal function only short-term after LT in the intention

158 mption leads to overproduction of urates and renal function plays a critical role in serum uric acid

159 Of these, 70.3% experienced improved renal function within 48 hours.

160 nt failure rates, delayed graft function and renal function, and patient and graft survival were not

161 e into demonstrable gains in preservation of renal function, despite an apparent trend to improvement

162 less and adequate haematologic, hepatic, and renal function.

163 culminating in progressive deterioration of renal function.

164 es: body mass index, sex, age, diabetes, and renal function.

165 ction, patient and graft survival rates, and renal function.

166 f renal cells is an important determinant of renal function.

167 audition, regulation of blood pressure, and renal function.

168 ipidemia, the metabolic syndrome or impaired renal function.

169 i) Intestinal and renal histopathology; (ii) Renal function; (iii) Cellular signaling changes; (iv) O

170 After treatment, renal functional recovery was best with histological ATN

171 in the presence of impaired respiratory and renal functions.

172 option for donation after circulatory death renal grafts compared with conventional hypothermic meth

173 activity, is a humoral factor that regulates renal health.

174 Outcome measures were: (i) Intestinal and renal histopathology; (ii) Renal function; (iii) Cellula

175 ADC and renal hypoxia (R2*) by blood-oxygen-level-dependent MRI

176 al tubule-forming cells aimed at alleviating renal hypoxia and enhancing tubulogenesis holds promise

177 filtration rate (GFR), a measure of relative renal hypoxia, in adolescents with and without type 1 di

178 00-1.01, increase per 10x9 decrease), severe renal impairment (aOR 5.14, 95%CI 2.65-9.97), and low al

179 Data on bone health and renal impairment in people with human immunodeficiency v

180 n dialysis or with a kidney transplant): (1) Renal Impairment in Secondary Care (RIISC, Queen Elizabe

181 ad severe congestive heart failure or severe renal impairment were excluded.

182 management of patients with both cancer and renal impairment.

183 outcome of NTS in C57BL/6 mice by decreasing renal infiltration and proliferation of T cells, which r

184 Glp1r(-/-) mice displayed increased renal infiltration of neutrophils and T cells after indu

185 f Tris DBA on glomerular cell proliferation, renal inflammation, and immune cells.

186 ating pathways and of hematopoietic GSTM1 on renal inflammation.

187 talization (OR, 2.9; 95% CI, 1.3-6.7), acute renal injury (OR, 2.7; 95% CI, 1.3-5.6), and CRP on admi

188 ic landscape at the single-cell level during renal injury and the resolution of fibrosis.

189 mportantly, aggravation of cisplatin-induced renal injury caused by Vgf gene ablation is partly rever

190 treptozotocin model of hyperglycemia-induced renal injury ENaC activity in hyperglycemic animals was

191 ns and bile acids, might mediate parenchymal renal injury in patients with cirrhosis, suggesting that

192 Lower ADC potentially reflects renal injury in RVD patients, but does not change in res

193 -, cisplatin-, and rhabdomyolysis-associated renal injury.

194 m 3,939 participants enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 and

195 CKD participating in the multicenter Chronic Renal Insufficiency Cohort (CRIC) Study.

196 In 3655 participants of the Chronic Renal Insufficiency Cohort study, we evaluated the assoc

197 ve septic shock (4.0-fold, 95% CI 3.58-4.43) renal insufficiency/failure (3.3-fold, 95% CI 2.91-3.65)

198 21 did not increase urine Na(+) excretion or renal interstitial cGMP in SHR.

199 ANCA-associated vasculitis (AAV) and severe renal involvement is not established.

200 importance of WNK's cellular degradation on renal ion transport.

201 red to P2X4 wild-type (WT) mice subjected to renal IR.

202 promising therapeutic approach to attenuate renal IRI.

203 out mice lacking periostin expression in the renal ischemia-reperfusion injury model, and primary cul

204 It is also overexpressed after renal ischemia-reperfusion, an event that induces kidney

205 Similarly, in a rat model of renal ischemia/reperfusion injury, SAR247799 preserved r

206 ferations) and chronic (tubulo-interstitial) renal lesions in total renal cortex.

207 FAIP6, FAR2) and chronic (LTB, CXCL6, ITGAX) renal lesions that were validated by RT-PCR and IHC.

208 nd the mean HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predis

209 We describe 2 cases of renal lymphangiectasia in transplanted kidneys, both fro

210 ury on the ability of donor-derived resident renal macrophages to act as professional antigen-present

211 nuria as well as the other commonly observed renal manifestations of LS.

212 se series of patients with a newly diagnosed renal mass who were referred for surgery was examined.

213 When faced with the finding of a small renal mass, radiologists must determine whether it is be

214 malignant renal tumors compared with benign renal masses, supporting further assessment of DPSMA as

215 rated DPSMA uptake and kinetics in localized renal masses.

216 as a potential tool for evaluating localized renal masses.

217 of MRI for lipid-poor AMLs in patients with renal masses.

218 Renal medullary carcinoma (RMC) is a highly lethal malig

219 ovascular procedure, whereby the ablation of renal nerves results in reduced renal afferent and effer

220 for OCT1 and additional cation transporters (renal OCT2, MATE1, and MATE2K).

221 In particular, renal oncocytoma and chromophobe RCC, which present the

222 inct mechanisms of OXPHOS exist in chRCC and renal oncocytoma and that expression levels of ETC compl

223 s of renal tissues, including normal kidney, renal oncocytoma, and renal cell carcinomas (RCC).

224 During renal ontogeny, expression of these factors colocalized

225 ute heart failure clinical trials: ROSE-AHF (Renal Optimization Strategies Evaluation in Acute Heart

226 Most (93%) had undergone renal or liver transplantation.

227 glutide treatment significantly improved the renal outcome of NTS in C57BL/6 mice by decreasing renal

228 fatal and non-fatal heart failure events and renal outcomes in all randomly assigned patients with HF

229 domized, controlled trials in which improved renal outcomes occur only in the subgroup of patients wi

230 Cardiovascular and renal outcomes with empagliflozin in heart failure.

231 SGLT2 inhibitors improve cardiovascular and renal outcomes, including hospitalization for heart fail

232 1,25D, but not FGF23, levels predicted poor renal outcomes.

233 lozin can reverse isoprenaline (ISO)-induced renal oxidative damage in rats, a model that mimics SNS

234 ve of this study was to compare the ratio of renal oxygen availability (RO(2)) to glomerular filtrati

235 Renal oxygenation, eGFR, and SCr improved after MT + PTR

236 Progressive renal pathologies, including fibrosis, mesangial matrix

237 henotype and functions of these cells in the renal pelvis.

238 ICs are a minor population of ICs in murine renal pelvis.

239 ssures or renal venous pressures to increase renal perfusion.

240 for lymphatics playing a fundamental role in renal physiology and pathology and treatments modulating

241 s (T1D) and relate the ratio to albuminuria, renal plasma flow (RPF), fat mass, and insulin sensitivi

242 nal antagonist, siponimod, conferred minimal renal protection and desensitized S1P(1) These findings

243 ay also have roles in primary prevention and renal protection.

244 In vitro exposure of human renal proximal tubular epithelial cells to C5a led to al

245 Additional frequent findings included renal proximal tubular injury, focal pancreatitis, adren

246 The results demonstrate a primary renal proximal tubule cell AT(2)R natriuretic defect in

247 siology, toxicology, and pharmacology of the renal proximal tubule.

248 patients, persistent AKI and the absence of renal recovery are associated with distinct early and su

249 ete understanding of the molecular basis for renal recovery.

250 logenesis holds promise as the basis for new renal regenerative therapies.

251 high-risk group were more likely to require renal replacement therapy (odds ratio, 10.4; 95% CI, 5.9

252 opment of HUS (primary outcome) and need for renal replacement therapy (RRT) (secondary outcome) in S

253 7-day AKI, or on the need for postoperative renal replacement therapy after adjustments for confound

254 higher risk of acute kidney injury requiring renal replacement therapy in SOT vs. non-SOT patients (3

255 Continuous renal replacement therapy is associated with reduced amm

256 the risk of mortality is high, especially if renal replacement therapy is needed.

257 Acute kidney injury requiring renal replacement therapy occurred in 20% of SOTr compar

258 easible in ICU patients requiring continuous renal replacement therapy.

259 Renal resistive index was measured within 12 hours after

260 yal Hospital, Salford, UK, N = 861), and (3) Renal Risk in Derby (RRID, Derby, UK, N = 1,739).

261 diabetes in rats combined with a cardiac or renal stressor, would mimic diabetic cardiomyopathy and

262 emia/reperfusion injury, SAR247799 preserved renal structure and function at doses that did not induc

263 lutional neural network to segment six major renal structures: glomerular tuft, glomerulus including

264 Renal sympathetic denervation is the most extensively in

265 outgrowth in the development of a functional renal system, and has a putative role in the pathogenesi

266 stribution, have shown promising results for renal therapy.

267 bolic and lipid profiles of various types of renal tissues, including normal kidney, renal oncocytoma

268 No grade 3/4 renal toxicity occurred.

269 Here, we used a syngeneic rat renal transplant and IRI model to evaluate the therapeut

270 e information about the processes underlying renal transplant dysfunction and can be used for the dev

271 management of TRAS in patients with impaired renal transplant function.

272 ell-documented patient cohort (n = 892) in a renal transplant program with protocol biopsies was used

273 ion, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipien

274 From 1988 consecutive renal transplant recipients, we analyzed 179 patients un

275 -INT was evaluated in 2055 biopsies from 775 renal transplant recipients.

276 c antibodies (DSA) and poorer outcomes after renal transplantation (RTx).

277 matching and patient risk stratification in renal transplantation is the single antigen bead (SAB) a

278 idney function following IRI and survival of renal transplants.

279 exus of the regulatory pathways for multiple renal transport processes.

280 nofibrate decreased the elevated hepatic and renal triglyceride and hepatic glycogen levels found in

281 In vitro, SCFAs modulated inflammation in renal tubular cells and podocytes under hyperglycemic co

282 Albumin induced features of ER stress in renal tubular cells with ATF3/ATF4 activation.

283 eceptor 2 (TNFR2) is strongly upregulated on renal tubular epithelial cells by acute cell-mediated re

284 F) with tenofovir alafenamide (TAF) improves renal tubular markers in HIV-infected individuals but th

285 NAD(+)-dependent maintenance of renal tubular metabolic health may also attenuate long-t

286 t ischemic AKI with significantly attenuated renal tubular necrosis, inflammation, and apoptosis when

287 Protein abundance along the renal tubule for many commonly studied water and solute

288 ned cell therapy of vessel-forming cells and renal tubule-forming cells aimed at alleviating renal hy

289 with a 2100 Da PEG molecule (ICG-PEG45) as a renal-tubule-secreted near-infrared-emitting fluorophore

290 e, decreased mtDNA levels were visualized in renal tubules as a function of aging, which was prevente

291 ized by formation of 2,8-DHA crystals within renal tubules.

292 tatistical modeling allows discrimination of renal tumors and has the potential to be used in the cli

293 e evaluate the growth of genetically defined renal tumors and their association with patient clinical

294 correlate with PSMA expression in malignant renal tumors compared with benign renal masses, supporti

295 alterations, but only subtle alterations of renal urate excretion and ABCG2 abundance.

296 A, and significant evidence of reduced extra-renal urate excretion.

297 own by immunostaining of endothelial makers, renal vascular densities were decreased accompanied by i

298 n, morphological assessment showed decreased renal vasculature, particularly of the glomerular capill

299 Pullers reduce central venous pressures or renal venous pressures to increase renal perfusion.

300 Vasopressin regulates renal water excretion by binding to a G(alpha) s-coupled